sinc
recommend
implement
blood
safeti
commun
blood
collector
blood
safeti
expert
relev
feder
agenc
respond
emerg
infecti
diseas
eid
threat
west
nile
viru
wnv
recent
xenotrop
murin
leukemia
virusrel
viru
xmrv
respond
new
threat
entail
assess
risk
blood
suppli
recipi
health
evalu
best
manag
andor
control
potenti
risk
commun
inform
blood
donor
recipi
physician
gener
public
although
fda
regulatori
author
develop
guidanc
document
new
regul
respons
eid
threat
base
avail
data
challeng
gener
data
respond
potenti
risk
requir
concert
coordin
action
multipl
ph
agenc
center
diseas
control
prevent
cdc
fda
nation
institut
health
nih
broader
transfus
medicin
commun
aabb
blood
provid
therefor
incumb
upon
transfus
medicin
profession
collect
provid
robust
data
time
manner
policymak
inform
decis
process
well
take
activ
role
risk
commun
stakehold
must
recogn
provid
leadership
time
research
risk
assess
must
take
hard
look
respons
learn
lesson
histori
process
involv
confirm
critic
done
previou
respons
potenti
threat
blood
suppli
assess
respons
improv
futur
threat
aftermath
recent
xmrv
investig
inevit
occurr
futur
infecti
threat
nation
heart
lung
blood
institut
nhlbi
conven
expert
task
forc
charg
evalu
lesson
previou
eid
blood
safeti
threat
assess
could
use
optim
futur
respons
strategi
task
forc
ask
review
discuss
respons
past
epidem
recent
eid
consid
work
could
work
better
data
necessari
assess
blood
safeti
risk
need
engag
evalu
risk
stakehold
method
andor
process
need
place
resourc
infrastructur
capac
need
best
train
futur
expert
scientif
cultur
encourag
encourag
cooper
first
session
respons
earlier
epidem
examin
follow
discuss
respons
recent
agent
concern
includ
indepth
look
latest
potenti
threat
xmrv
gener
overview
agent
potenti
concern
horizon
ensu
follow
gener
discuss
lesson
learn
consider
futur
strategi
report
summar
result
discuss
michael
p
busch
md
phd
blood
system
research
institut
univers
california
san
franciscoth
possibl
aid
could
transmit
blood
blood
product
first
formal
discuss
decemb
morbid
mortal
weekli
report
mmwr
almost
month
first
report
pneumocysti
carinii
pneumonia
patient
hemophilia
almost
month
first
report
p
carinii
pneumonia
homosexu
men
januari
cdc
conven
workgroup
review
exist
inform
transfusionand
factor
concentrateassoci
aid
case
identifi
opportun
prevent
aid
blood
recipi
person
hemophilia
time
person
hemophilia
account
six
report
aid
case
five
addit
case
establish
possibl
transfus
relat
larg
lookback
program
found
aid
patient
interview
san
francisco
report
donat
blood
previou
year
statement
issu
later
januari
cdc
workgroup
simpli
note
possibl
blood
born
transmiss
still
unproven
rais
furthermor
caus
aid
still
unknown
januari
exist
data
show
vast
major
homosexu
men
intraven
iv
drug
user
test
posit
surrog
marker
antibodi
hepat
b
viru
hbv
antihbc
workgroup
remark
use
nonspecif
marker
evalu
agenc
took
respons
prevent
transfusiontransmit
aid
although
workgroup
consid
sever
intervent
exclud
risk
group
donat
blood
concern
adopt
confront
approach
toward
potenti
higherrisk
donor
thu
statement
note
direct
indirect
question
regard
donor
sexual
prefer
inappropri
nonetheless
blood
bank
san
francisco
develop
process
wherebi
donor
could
discreetli
exclud
answer
ye
block
question
known
aid
risk
factor
mani
blood
collect
organ
particularli
citi
high
risk
adopt
donor
qualif
process
known
selfdeferr
present
donor
provid
inform
aid
risk
factor
risk
factor
ask
donat
also
outreach
homosexu
commun
organ
discourag
donat
atrisk
men
new
york
citi
later
elsewher
confidenti
unit
exclus
procedur
introduc
allow
individu
give
blood
inform
blood
bank
nondisclos
risk
behavior
blood
unit
would
discard
use
research
blood
bank
san
francisco
bay
area
also
began
implement
surrog
test
tcell
helpersuppressor
ratio
stanford
univers
blood
bank
antihbc
test
blood
donor
irwin
memori
blood
bank
note
flow
cytometri
equip
perform
tcell
ratio
avail
outsid
limit
research
lab
antihbc
test
yield
mani
fals
posit
confirmatori
test
avail
moreov
concern
posit
surrog
test
would
concern
donor
homosexu
men
would
donat
blood
simpli
get
test
elimin
homosexu
donor
would
neg
affect
blood
suppli
homosexu
commun
learn
potenti
risk
mani
commun
stop
donat
blood
great
concern
arisen
patient
commun
gener
fear
blood
origin
san
francisco
addit
perform
characterist
antihbc
test
remain
concern
larger
studi
transfusiontransmit
aid
publish
januari
decemb
number
transfusionrel
aid
case
risen
hiv
discov
spring
high
rate
viru
isol
antibodi
detect
homosexu
men
sever
studi
point
viru
caus
agent
aid
question
potenti
donor
optim
blood
bank
expect
hiv
test
would
soon
avail
yet
hiv
antibodi
test
avail
lookback
studi
found
donor
test
posit
hiv
also
reactiv
antihbc
approxim
recipi
transfus
blood
hivinfect
suspect
case
acquir
infect
analysi
donat
histori
hivinfect
donor
san
francisco
hiv
infect
preval
among
homosexu
men
san
francisco
hiv
donat
rate
subsequ
identifi
infect
donor
estim
incid
transfusiontransmit
hiv
infect
rose
rapidli
first
occurr
peak
approxim
per
unit
transfus
recipi
san
francisco
alon
infect
hiv
transfus
analysi
also
show
donor
select
educ
effort
effect
curb
number
donat
infect
individu
donat
individu
later
test
posit
hiv
develop
clinic
aid
declin
time
antihbc
test
implement
time
hivspecif
test
avail
hope
implement
hiv
antibodi
test
would
elimin
transfusiontransmit
aid
breakthrough
case
detect
shortli
introduct
hiv
test
indic
antibodi
screen
elimin
risk
case
relat
primarili
homosexu
men
initi
test
neg
antihiv
later
seroconvert
donat
blood
led
improv
donor
elig
criteria
includ
exclus
male
sex
anoth
male
sinc
studi
found
infecti
window
period
day
infect
detect
antibodi
convers
firstgener
screen
assay
later
improv
sensit
antibodi
assay
reduc
preseroconvers
infecti
window
period
approxim
week
subsequ
addit
antigen
replac
nucleic
acid
test
nat
virtual
elimin
window
result
current
risk
estim
approxim
infecti
unit
per
million
transfus
unit
fact
six
transmiss
report
unit
state
sinc
nat
implement
time
million
whole
blood
wb
donat
per
year
process
distribut
even
impress
implement
viral
inactiv
step
addit
donor
select
hiv
test
elimin
transmiss
hiv
plasma
deriv
case
report
year
experi
transfusiontransmit
aid
show
infect
agent
long
asymptomat
incub
period
spread
blood
suppli
year
recognit
result
fatal
infect
transfus
recipi
blood
banker
slow
recogn
magnitud
problem
implement
addit
safeti
procedur
enhanc
donor
select
surrog
test
plasma
treatment
measur
might
reduc
hiv
transmiss
even
hiv
screen
implement
took
sever
year
address
persist
risk
windowphas
hiv
infect
yet
failur
led
transform
blood
safeti
field
highli
regul
sciencebas
field
proactiv
address
potenti
transfusionrel
eid
respons
hivaid
slow
viru
differ
seen
previous
etiolog
agent
identifi
serolog
deploy
epidemiolog
hiv
infect
unclear
long
latenc
infect
symptom
high
diseas
risk
infect
person
becam
clear
serolog
possibl
respond
initi
uncertainti
surround
hiv
requir
new
paradigm
precaut
foreign
blood
commun
prefer
wait
certain
inform
interven
aggress
uniformli
start
march
three
hiv
test
quickli
licens
abil
respond
futur
threat
move
test
approv
process
may
also
take
long
time
emphas
import
stakehold
includ
manufactur
blood
commun
fda
involv
soon
possibl
roger
dodd
phd
american
red
crossvir
hepat
long
recogn
major
advers
outcom
transfus
inde
earli
prospect
studi
suggest
blood
recipi
affect
hepat
b
differenti
epidemiolog
clinic
ground
discoveri
hepat
b
surfac
antigen
hbsag
time
posttransfus
hepat
pth
thought
entir
due
hbv
insensit
test
hbsag
implement
blood
safeti
measur
start
limit
impact
pth
although
much
greater
impact
attribut
care
donor
select
method
avoid
paid
donat
even
introduct
highli
sensit
radioimmunoassay
reduc
incid
pth
recognit
hepat
viru
hav
develop
diagnost
test
reveal
vast
major
residu
pth
due
hav
hbv
term
nona
non
b
hepat
nanbh
coin
effort
identifi
caus
agent
start
succeed
meantim
larg
multicent
prospect
studi
pth
execut
studi
reveal
epidemiolog
relationship
surrog
marker
elev
alanin
aminotransferas
alt
level
presenc
antihbc
donor
pth
recipi
introduct
donor
test
surrog
marker
predict
reduc
nanbh
transmiss
test
wide
implement
delay
attribut
number
factor
includ
concern
loss
donor
uncertainti
true
sever
nanbh
need
manag
hivaid
epidem
recognit
character
nanbh
involv
studi
sever
disciplin
includ
epidemiolog
patholog
prospect
clinic
posttransfus
studi
new
solut
need
overcom
uniqu
challeng
present
nanbh
hepat
virus
could
grown
tissu
cultur
investig
reli
inocul
nonhuman
primat
addit
unlik
hbv
proven
possibl
detect
antibodi
put
caus
agent
today
rapid
pathogen
discoveri
techniqu
avail
hepat
c
viru
hcv
clone
incred
painstak
manual
process
result
arduou
clone
experi
use
plasma
blindli
passag
chimpanze
infect
nanbh
belief
agent
envelop
gaviru
hcv
eventu
identifi
specif
test
antibodi
hcv
develop
becam
clear
essenti
nanbh
due
transmiss
hcv
routin
test
antibodi
firstgener
assay
implement
follow
implement
antibodi
test
increas
sensit
start
nat
hcv
addit
implement
current
estim
residu
risk
transfusiontransmit
hcv
unit
state
per
million
blood
compon
experi
nanbh
illustr
power
persist
teach
us
lesson
benefit
risk
surrog
test
although
test
use
elimin
potenti
infect
donor
mani
donor
exclud
even
though
carrier
hcv
addit
lesson
nanbh
andor
hcv
stori
might
appli
centuri
exampl
viru
associ
sever
acut
respiratori
syndrom
sar
identifi
within
hour
sampl
receiv
hand
recogn
like
increas
use
molecular
genet
genom
method
identifi
virus
lead
discoveri
mani
virus
without
associ
diseas
examin
emerg
threat
mean
ignor
exist
threat
respons
nanbh
prolong
part
scientif
commun
focus
hiv
major
discuss
regard
nanbh
surrog
test
focus
need
protect
patient
potenti
impact
donor
deferr
blood
avail
aid
epidem
caus
massiv
shift
focu
blood
safeti
current
era
molecular
virolog
mani
virus
identifi
without
associ
diseas
baselin
estim
viral
sequenc
human
yet
establish
human
microbiom
activ
investig
two
nih
grant
specif
address
plasma
viral
discoveri
program
virus
hcv
hiv
remain
signific
public
health
problem
develop
world
face
constraint
implement
resourceintens
solut
use
develop
world
nih
blood
bank
evalu
alt
test
implement
indic
appear
effect
reduc
nanbh
case
costbenefit
analysi
unabl
defin
precis
financi
estim
benefit
alt
test
surrog
test
agent
remain
controversi
although
strict
interpret
precautionari
principl
would
encourag
use
test
approach
virem
donat
interdict
first
year
test
approxim
frozen
blood
product
highincid
area
withdrawn
sinc
larg
number
wnvposit
blood
donat
identifi
primarili
minipool
nat
six
transmiss
recogn
transmiss
season
retrospect
individu
wnv
nat
store
donor
sampl
demonstr
lowlevel
viremia
asymptomat
donor
miss
minipool
test
result
develop
implement
algorithm
convert
blood
region
pool
sensit
individualdon
id
test
interv
wnv
activ
donor
trigger
evolv
recogn
oper
burden
inher
test
id
aliquot
aabb
associ
bulletin
recommend
idnat
trigger
two
presumpt
virem
donor
seen
within
roll
day
made
recommend
establish
atrisk
donor
popul
within
collect
area
wnv
activ
donor
test
monitor
real
time
convert
idnat
within
hour
reach
trigger
id
aliquot
test
continu
minimum
day
virem
donor
six
addit
case
transfusiontransmit
wnv
recogn
perspect
occur
background
blood
compon
transfus
annual
case
attribut
primarili
insensit
trigger
ineffici
commun
neighbor
center
accordingli
trigger
continu
reassess
system
singl
virem
donor
presenc
wnv
activ
commun
may
use
implement
id
screen
addit
base
model
cdc
system
extend
id
screen
week
beyond
last
virem
donat
commun
blood
safeti
commun
reinforc
exampl
use
process
includ
email
notif
tree
daili
examin
aabbwnv
biovigil
network
websit
public
health
wnv
surveil
sourc
design
ensur
overlap
collect
region
awar
donor
activ
area
trigger
id
screen
multipl
organ
even
absenc
virem
donor
one
collect
facil
experi
wnv
also
foster
collabor
scientif
public
impact
beyond
blood
commun
increas
understand
clinic
express
biolog
epidemiolog
wnv
unit
state
exampl
allow
estim
popul
incid
rate
area
high
donor
incid
use
season
wnv
test
discuss
measur
enhanc
sensit
wnv
detect
blood
donor
program
involv
potenti
suspens
test
winter
human
activ
minim
combin
plan
convers
id
test
histor
high
incid
week
month
anticip
detect
donor
infect
step
might
enhanc
capac
convert
id
test
transmiss
season
conserv
resourc
test
facil
lowincid
period
propos
base
observ
virem
donor
report
aabb
biovigil
websit
identifi
midapril
middecemb
respons
wnv
rapid
appropri
success
model
respond
emerg
infecti
agent
success
possibl
part
rapid
consensu
need
interven
littl
controversi
appropri
technolog
nat
requir
contrast
respons
nanbh
delay
part
concern
nonspecif
intervent
might
harm
good
publicpriv
partnership
critic
success
respons
wnv
emerg
appropri
deploy
wnv
nat
prevent
maximum
number
case
yet
determin
pauciti
transfus
transmiss
recent
year
valid
iter
approach
trigger
id
test
evolv
sever
transmiss
season
expand
id
test
peak
transmiss
interv
summer
discuss
tini
number
transfusiontransmit
infect
recent
season
one
year
suggest
valu
may
minim
barrier
includ
larg
increas
reagent
consum
consumpt
staf
highthroughput
nat
laboratori
susan
l
stramer
phd
american
red
crosstrypanosoma
cruzi
parasit
respons
chaga
diseas
result
chronic
infect
silent
decad
although
infect
less
preval
north
america
endem
area
south
central
america
report
two
transplantassoci
case
lo
angel
california
state
preval
chaga
diseas
north
america
might
higher
previous
thought
particularli
region
larg
proport
donor
emigr
chagasendem
countri
recent
studi
risk
factor
cruzi
antibodyposit
blood
donor
identifi
autochthon
transmiss
within
unit
state
may
also
common
previous
thought
vast
major
antibodi
confirmedposit
donor
identifi
american
red
cross
risk
virtu
born
resid
endem
area
studi
attempt
identifi
atrisk
donor
direct
question
proven
ineffect
strategi
lack
sensit
specif
rbc
pathogen
reduct
avail
donor
ask
health
histori
question
predon
interview
regard
histori
babesiosi
approach
insensit
question
regard
tick
bite
also
insensit
sinc
nymphal
stage
tick
requir
blood
meal
growth
small
recogn
attach
tick
remov
promptli
attach
period
requir
babesia
transmiss
fdalicens
test
avail
donor
screen
although
investig
new
drug
applic
place
use
antibodi
nat
ensur
earli
antibodyneg
infect
later
infect
lower
level
parasit
may
detect
dengu
import
arthropod
vector
born
diseas
world
caus
one
four
type
dengu
virus
world
popul
approxim
billion
peopl
consid
risk
million
case
occur
annual
occur
explos
outbreak
tropic
subtrop
approxim
case
dengu
viru
infect
unappar
also
rang
sever
mild
nonspecif
acut
febril
diseas
refer
dengu
fever
sever
dengu
previous
refer
dengu
hemorrhag
fever
dengu
shock
syndrom
nine
countri
experienc
sever
dengu
epidem
diseas
emerg
reemerg
countri
vcjd
human
form
bovin
spongiform
encephalopathi
prionassoci
degen
alway
fatal
diseas
lengthi
incub
period
year
major
vcjd
case
report
worldwid
octob
observ
unit
kingdom
n
vcjd
first
recogn
distinct
agent
three
known
case
remain
aliv
although
similar
sporad
iatrogen
famili
cjd
vcjd
occur
primarili
among
younger
individu
present
psychiatr
symptom
gener
longer
cours
diagnosi
death
four
case
transfusiontransmit
vcjd
recogn
three
result
develop
vcjd
recipi
fourth
occur
individu
die
underli
diseas
found
harbor
agent
spleen
least
one
lymph
node
note
transmiss
nonleukoreduc
blood
compon
fifth
possibl
transmiss
factor
viii
concentr
three
vcjd
case
report
unit
state
two
aros
exposur
unit
kingdom
aros
exposur
saudi
arabia
data
recent
studi
suggest
blood
compon
transmit
vcjd
prion
whether
leukoreduc
leukoreduct
case
plt
extend
incub
period
day
sheep
experiment
model
experiment
transmiss
human
case
recipi
known
exposur
blood
donor
later
develop
vcjd
highlight
high
rate
infect
among
individu
expos
transfus
although
risk
vcjd
appear
declin
number
expos
individu
unknown
second
wave
infect
possibl
intervent
consist
primarili
donor
deferr
base
histori
travel
unit
kingdom
affect
countri
implement
evid
transfusionassoci
transmiss
report
efficaci
strategi
unknown
implement
balanc
theoret
risk
reduct
manag
donor
loss
expect
exceed
present
donor
licens
test
avail
donor
screen
develop
licensur
implement
screen
test
unlik
unit
state
vigil
critic
sinc
varieti
agent
may
emerg
may
share
common
characterist
none
common
prior
agent
blood
safeti
intervent
introduc
intervent
may
requir
even
document
transfus
transmiss
eg
vcjd
infect
gamma
retrovirus
simpl
virus
accessori
gene
lead
sustain
viremia
induc
solid
tumor
immun
dysfunct
neurolog
disord
octob
scienc
publish
report
gamma
retroviru
xmrv
detect
previous
prostat
cancer
tissu
detect
blood
cell
patient
chronic
fatigu
syndrom
cf
observ
consist
previou
studi
show
appar
cluster
cf
tempor
associ
cf
acut
xmrv
infect
immun
defici
similar
seen
prostat
cancer
scienc
articl
report
investig
detect
xmrv
patient
cf
also
almost
healthi
control
xmrv
infect
could
seen
peripher
blood
mononuclear
cell
pbmnc
plasma
author
thu
rais
possibl
xmrv
infect
contribut
pathogenesi
cf
accompani
commentari
note
light
presenc
infecti
viru
plasma
blood
cell
bloodborn
transmiss
possibl
respons
potenti
eid
threat
dhh
immedi
facilit
establish
coordin
collabor
group
intern
extern
dhh
aabb
interorganiz
task
forc
dhhsnhlbi
blood
xmrv
scientif
research
work
group
srwg
former
took
lead
risk
manag
risk
commun
aspect
respons
wherea
latter
charg
design
coordin
research
studi
evalu
whether
xmrv
pose
threat
blood
safeti
risk
assess
harvey
klein
md
nih
bethesdawithin
day
scienc
public
aabb
conven
interorganiz
task
forc
charg
review
avail
data
recommend
action
consid
mitig
potenti
risk
bloodborn
transmiss
advis
aabb
way
inform
donor
recipi
physician
gener
public
risk
transfusionrel
transmiss
xmrv
among
evid
review
task
forc
scienc
articl
proceed
nation
academi
scienc
report
show
presenc
murin
leukemia
viru
mlv
nucleic
acid
na
distinct
sequenc
level
xmrv
cf
patient
control
primat
studi
suggest
iv
inject
xmrv
led
viremia
seroconvers
describ
tissu
tropism
also
neg
data
unit
state
sever
countri
although
task
forc
never
met
face
face
monthli
teleconfer
kept
particip
current
publish
unpublish
inform
electron
commun
circul
prepubl
member
task
forc
postul
sever
reason
discord
result
includ
geograph
differ
popul
nonvalid
assay
differ
definit
cf
laboratori
contamin
basi
inconsist
avail
data
task
forc
consensu
aabb
adopt
precautionari
polici
donor
educ
selfdeferr
person
histori
cf
polici
institut
wide
unit
state
canada
summari
data
task
forc
polici
publish
transfus
data
becam
avail
includ
recombin
origin
xmrv
laboratori
mice
evid
point
contamin
reagent
recombin
agent
basi
data
task
forc
conclud
observ
posit
result
repres
fals
posit
evid
xmrv
pose
transfus
risk
experi
show
interorganiz
task
forc
form
rapidli
inclus
represent
major
stakehold
provid
task
forc
credibl
addit
publicpriv
partnership
task
forc
could
share
unpublish
inform
form
consensu
posit
effect
allow
member
organ
autonomi
decid
whether
act
posit
perform
altern
action
moreov
task
forc
present
singl
voic
focus
rapidli
evolv
issu
help
address
inquiri
press
reaction
pressur
patient
popul
import
dynam
gener
call
action
term
blood
safeti
sever
polytrop
virus
xmrv
one
group
also
report
found
sever
na
sequenc
variant
virus
thu
addit
uncertainti
virus
might
associ
cf
possibl
neg
effect
promulg
requir
earli
fda
will
work
cooper
privat
sector
altern
action
certainti
exampl
fda
feel
industri
respond
appropri
potenti
threat
blood
suppli
withhold
action
robust
process
need
decid
stakehold
particip
decis
make
verifi
implement
recommend
risk
inform
interpret
differ
differ
member
task
forc
addit
case
uncertainti
respons
potenti
threat
differ
group
jurisdict
although
aabb
task
forc
promot
agreement
among
member
decis
statement
agreement
might
necessari
uniform
process
evalu
evolv
inform
place
standard
criteria
valu
address
group
make
decis
process
allow
group
better
explain
differ
respons
simon
glynn
md
msc
mph
nhlbi
nih
bethesdath
hhsnhlbi
blood
xmrv
srwg
charg
design
coordin
studi
evalu
whether
xmrv
pose
threat
blood
safeti
sever
question
need
address
srwg
could
first
conven
appropri
function
engag
particip
srwg
resourc
andor
infrastructur
need
research
go
fund
srwg
conduct
studi
respons
first
question
clear
multidisciplinari
approach
essenti
thu
srwg
brought
togeth
retrovirologist
xmrv
experi
expert
field
cf
myalgic
encephalomyel
blood
bank
transfusiontransmit
infecti
diseas
expert
statist
epidemiolog
expert
blood
product
regulatori
expert
liaison
srwg
aabb
interorganiz
task
forc
also
appoint
nhlbi
chair
charg
report
ph
blood
organ
tissu
senior
execut
committe
report
blood
secretari
director
assist
secretari
health
work
group
also
engag
relev
advocaci
group
develop
manufactur
highthroughput
xmrvnat
andantibodi
assay
time
time
work
ad
hoc
expert
srwg
particip
organ
provid
support
term
effort
scientif
expertis
nhlbi
provid
necessari
administr
support
hh
laboratori
fund
research
test
manufactur
fund
test
panel
sampl
nonhh
laboratori
supplement
ongo
nhlbi
retroviru
epidemiolog
donor
studi
red
ii
research
program
grant
support
work
central
laboratori
nonhh
laboratori
involv
procur
test
biospecimen
redsii
data
coordin
center
provid
necessari
independ
statist
expertis
assess
eid
risk
context
blood
safeti
requir
answer
three
basic
question
infecti
agent
present
blood
donor
transfus
transmit
clinic
impact
srwg
first
evalu
relev
literatur
includ
xmrvrelat
report
anim
studi
observ
studi
evalu
associ
exist
cf
prostat
cancer
transfus
histori
review
srwg
decid
concentr
answer
first
questioni
xmrv
blood
suppli
end
srwg
focus
evalu
assay
identifi
quantifi
viral
na
antibodi
establish
preval
xmrv
infect
among
blood
donor
three
studi
conduct
result
dissemin
soon
becam
avail
relev
stakehold
present
webinar
public
graham
simmon
phd
blood
system
research
institut
univers
california
san
franciscoa
part
blood
xmrv
srwg
task
design
coordin
research
studi
evalu
whether
xmrv
pose
threat
blood
safeti
literatur
review
three
laboratori
studiesphas
iiiwer
perform
care
review
current
state
epidemiolog
knowledg
potenti
associ
prostat
cancer
andor
cf
receipt
prior
blood
transfus
reveal
littl
associ
four
relev
studi
potenti
associ
blood
transfus
cancer
identifi
review
simmon
et
al
although
conclus
littl
evid
associ
blood
transfus
prostat
cancer
contrast
far
less
known
potenti
associ
cf
transfus
histori
one
peerreview
studi
could
identifi
blood
transfus
mention
relat
cluster
cf
case
instanc
report
none
case
receiv
transfus
thu
srwg
conclud
publish
evid
epidemiolog
link
suggest
transfus
transmiss
agent
link
either
prostat
cancer
cf
srwg
includ
sever
laboratori
assay
detect
na
xmrv
relat
mlv
includ
laboratori
previous
publish
detect
virus
blood
donor
healthi
popul
well
fail
detect
virus
popul
thu
decid
initi
phase
studi
srwg
would
compar
sensit
assay
use
analyt
panel
panel
consist
xmrvinfect
cell
cell
supernat
cell
dilut
wb
plasma
respect
mimic
potenti
clinic
sampl
gross
differ
sensit
particip
assay
detect
viral
na
observ
two
analyt
panel
thu
differ
detect
na
group
detect
viru
clinic
sampl
could
explain
lack
sensit
addit
number
particip
laboratori
use
assay
subsequ
studi
fail
detect
xmrv
mlv
blood
donor
popul
patient
cf
prostat
cancer
although
phase
studi
design
examin
assay
specif
gener
concern
term
falseposit
result
two
pilot
studi
clinic
sampl
cf
patient
previous
describ
xmrv
posit
perform
phase
ii
first
studi
unblind
design
identifi
best
sampl
type
wb
plasma
pbmnc
process
method
result
inconsist
thu
second
blind
studi
perform
use
sampl
four
patient
cf
previous
test
xmrv
posit
healthi
control
individu
previous
demonstr
xmrv
neg
four
laboratori
perform
na
detect
two
studi
serolog
respons
major
laboratori
three
four
unabl
detect
evid
xmrv
mlv
na
sampl
one
laboratori
fail
detect
serolog
respons
fourth
na
laboratori
unabl
report
result
due
intern
error
sampl
process
final
serolog
laboratori
report
three
four
patient
cf
seroposit
xmrv
control
also
found
posit
despit
previous
pedigre
neg
srwg
phase
iii
studi
assess
purportedli
xmrvor
mlvposit
sampl
neg
control
addit
nat
perform
three
blood
compon
serolog
viru
cultur
assay
also
perform
plasma
sampl
control
divid
distribut
nine
independ
laboratori
blind
test
six
seven
laboratori
perform
nat
found
posit
clinic
sampl
seventh
found
three
posit
sampleson
xmrv
mlv
clinic
sampl
set
two
neg
control
phylogenet
analysi
suggest
sequenc
like
aros
contamin
p
kellam
unpublish
analysi
among
two
laboratori
abl
report
viru
cultur
result
one
found
posit
sampl
second
report
presenc
xmrv
neg
control
compar
clinic
sampl
among
four
laboratori
conduct
serolog
test
two
report
posit
sampl
other
found
even
distribut
posit
sampl
among
neg
posit
control
addit
correl
sampl
two
laboratori
found
posit
despit
fact
run
assay
basi
result
srwg
note
laboratori
demonstr
reproduc
detect
xmrv
mlv
avail
assay
could
reproduc
detect
viru
antibodi
sampl
patient
previous
character
posit
work
group
thu
conclud
routin
screen
blood
donor
xmrv
mlv
warrant
sinc
work
publish
sever
addit
public
report
sign
xmrv
human
blood
donor
addit
public
found
associ
xmrv
cf
well
evid
detect
xmrv
clinic
sampl
result
contamin
multipl
sourc
report
eventu
led
retract
two
articl
report
detect
xmrv
cf
patient
control
donor
discuss
point
although
sever
articl
shown
evid
xmrv
mlv
human
blood
sampl
associ
xmrv
cf
prostat
cancer
sever
question
unresolv
exampl
clear
detect
rate
cf
sampl
two
origin
articl
observ
associ
vastli
differ
control
although
theori
repeat
sampl
handl
cf
patient
sampl
collect
case
decad
earlier
neg
control
seem
like
clear
whether
origin
studi
test
case
versu
control
blind
fashion
evid
xmrv
ever
enter
human
popul
creation
xmrv
passag
human
tissu
mice
illustr
novel
threat
could
come
crossspeci
transfer
agent
also
agent
gener
laboratori
respons
xmrv
occur
rapidli
deliber
respect
blood
safeti
horizon
steven
h
kleinman
md
univers
british
columbiath
classic
paradigm
emerg
threat
blood
suppli
assum
agent
caus
persist
asymptomat
infect
donor
infect
donor
continu
make
mani
infecti
blood
donat
likewis
experi
hiv
hcv
led
mani
assum
next
threat
spread
parenter
contact
associ
risk
behavior
recent
agent
wnv
dengu
vector
born
caus
transient
infect
would
caus
substanti
number
transfusiontransmit
case
infect
highli
preval
moreov
risk
infect
agent
depend
someon
live
travel
potenti
transfusiontransmiss
agent
requir
investig
might
discov
repositori
studi
viral
discoveri
program
without
associ
known
diseas
agent
associ
clinic
diseas
proven
transfus
transmit
time
discov
zoonot
agent
viru
underli
sar
spread
human
although
evid
establish
sar
viru
transmiss
transfus
blood
safeti
commun
mobil
outbreak
first
occur
likewis
evid
recent
measl
outbreak
transmit
transfus
enough
concern
work
group
issu
fact
sheet
although
arbovirus
wnv
caus
human
diseas
transmit
transfus
risk
transmiss
depend
outbreak
potenti
complic
epidemiolog
potenti
predict
retrovirus
particular
concern
potenti
latent
infect
mutagen
addit
transfus
bypass
bodi
natur
defens
therefor
highli
effici
rout
transmiss
thu
even
low
concentr
pathogen
transmit
base
volum
blood
transfus
moreov
mani
recipi
often
immunosuppress
therefor
develop
sever
clinic
diseas
infect
retrospect
analys
respons
hiv
hcv
along
concern
public
percept
led
reset
threshold
action
respond
potenti
threat
blood
suppli
even
theoret
risk
trigger
assess
possibl
action
wide
recogn
precautionari
threshold
might
result
action
indic
complet
inform
avail
aabb
eid
group
publish
review
agent
transfus
updat
web
inform
sheet
facilit
decis
make
respons
emerg
threat
committe
also
priorit
agent
four
group
base
public
health
regulatori
concern
amount
scientif
epidemiolog
evid
blood
safeti
risk
addit
expert
group
work
canadian
blood
servic
publish
model
risk
emerg
pathogen
enter
blood
suppli
model
predict
preval
rate
per
donor
rang
chronic
agent
like
hiv
per
rang
acut
agent
wnv
model
also
suggest
risk
period
defin
time
pathogen
enter
blood
suppli
time
effect
intervent
year
rang
year
acut
agent
year
rang
year
chronic
agent
light
concern
case
investig
includ
lookback
traceback
outbreak
investig
surveil
organ
transplant
recipi
popul
high
risk
symptomat
transfusiontransmit
infect
data
monitor
model
risk
need
evalu
emerg
agent
anim
inocul
experi
relat
level
viremia
parasitemia
infect
differ
stage
infect
vitro
studi
assess
viabil
organ
store
blood
compon
nhlbi
establish
five
link
donorrecipi
repositori
sever
donoronli
recipientonli
repositori
avail
test
frozen
repositori
donorrecipi
linkag
help
evalu
transfus
transmiss
provid
histor
perspect
preval
incid
repositori
usual
limit
particular
geograph
catchment
area
time
period
recipi
enrol
sampl
collect
difficult
expens
therefor
prospect
test
donor
cohort
valuabl
evalu
emerg
threat
face
new
challeng
discoveri
program
use
sensit
molecular
technolog
identifi
new
agent
might
appear
asymptomat
donor
known
diseas
associ
agent
discov
manner
might
associ
diseas
even
though
causat
yet
proven
stakehold
blood
safeti
public
health
mandat
maintain
surveil
effort
possibl
investig
agent
anim
model
human
mice
show
infecti
agent
diseas
transmiss
transmiss
might
secondari
extens
manipul
therefor
might
reflect
actual
risk
case
transfus
transmiss
might
theoret
possibl
likelihood
low
infrastructur
detail
plan
process
address
scenario
potenti
approach
might
differ
scenario
whether
gener
action
plan
creat
tailor
emerg
threat
whether
plan
intern
entiti
assum
respons
clear
clear
whether
nhlbifund
redsiii
project
organ
develop
toolbox
aid
plan
whether
toolbox
alreadi
exist
research
area
pathogen
inactiv
reduct
technolog
might
need
attent
first
challeng
address
implic
eid
identifi
agent
transmit
agent
whose
primari
transmiss
inhal
ingest
may
also
transmit
inject
includ
transfus
nation
intern
public
health
infrastructur
focu
common
mean
transmiss
possibl
agent
may
transmit
transfus
emerg
public
health
blood
transfus
commun
respond
reli
experi
gain
past
three
decad
blood
safeti
expert
learn
import
engag
stakehold
earli
collabor
process
develop
indepth
knowledg
laboratori
anim
infect
epidemiolog
studi
tool
dispos
develop
infrastructur
resourc
drawn
upon
blood
safeti
commun
varieti
riskreduct
approach
includ
introduct
specif
donor
deferr
criteria
implement
sensit
screen
test
limit
product
blood
compon
deriv
like
contain
agent
discontinu
collect
blood
specif
geograph
region
feasibl
agent
may
spread
improv
adher
evidencebas
conserv
use
blood
compon
implement
pathogen
reduct
method
inher
uncertainti
includ
identifi
eid
pose
threat
blood
safeti
manag
risk
base
imperfect
test
incomplet
data
reduc
unavoid
uncertainti
would
improv
futur
respons
strategi
task
forc
focus
sever
approach
strategi
enhanc
earli
recognit
potenti
threat
develop
formal
risk
assess
manag
action
plan
associ
set
tool
trigger
soon
new
threat
identifi
structur
coordin
addit
basic
translat
research
identifi
better
understand
potenti
eid
threat
assess
risk
import
train
futur
expert
studi
lombardi
colleagu
publish
stakehold
quickli
took
action
recogn
earli
potenti
implic
xmrv
although
sever
public
previous
associ
xmrv
prostat
cancer
recognit
xmrv
potenti
threat
blood
suppli
trigger
scienc
studi
note
presenc
xmrv
blood
healthi
control
widespread
recognit
xmrv
retroviru
thatif
confirm
present
bloodhad
potenti
establish
chronic
asymptomat
carrier
state
similar
seen
hiv
human
tlymphotrop
viru
use
xmrv
exampl
task
forc
particip
note
current
infecti
diseas
alert
system
case
public
articl
relat
commentari
prestigi
journal
refin
trigger
respons
potenti
threat
remain
ad
hoc
inconsist
although
informat
method
place
identifi
threat
bring
agent
forefront
remain
poorli
defin
softwar
global
program
avail
horizon
scan
system
modul
blood
safeti
final
unclear
criteria
short
demonstr
transfus
transmiss
relev
scientif
public
trigger
recognit
potenti
threat
newli
discov
agent
may
patent
mitig
threat
blood
suppli
lucr
investig
might
led
suggest
blood
screen
otherwis
inappropri
journal
scienc
trigger
ensur
appropri
peopl
alert
articl
publish
plan
place
find
could
appli
bioterror
threat
public
inform
obscur
journal
could
result
substanti
delay
recognit
public
health
implic
import
coher
approach
identifi
respond
potenti
brew
controversi
would
affect
evalu
whether
new
eid
agent
threat
although
mani
concern
find
lombardi
cowork
present
concern
overshadow
find
xmrv
almost
healthi
control
although
concern
express
via
internet
preliminari
result
neg
studi
took
time
comment
appear
highprofil
scientif
journal
interim
blood
safeti
commun
face
inabl
fulli
evalu
concern
public
task
forc
suggest
follow
strategi
enhanc
earli
recognit
dismiss
new
threat
creat
alert
system
journal
commun
blood
safeti
author
potenti
threat
blood
suppli
articl
publish
develop
process
quickli
releas
inform
emerg
scientif
controversi
relev
blood
safeti
includ
blood
safeti
exist
public
health
bioterror
horizonscan
system
blood
safeti
commun
respons
develop
initi
risk
assess
manag
action
plan
new
eid
threat
identifi
checklist
decis
tree
similar
use
feder
aviat
administr
respond
emerg
suggest
plan
must
develop
simultan
effort
corrobor
initi
find
develop
plan
also
least
consid
situat
inact
actual
best
cours
action
plan
includ
trigger
decis
point
guid
theoret
action
trigger
could
simpli
provid
impetu
consider
exampl
influenza
epidem
decis
tree
establish
stakehold
reconven
consid
potenti
action
time
threshold
trigger
approach
action
plan
flexibl
infecti
agent
differ
one
respons
fit
situat
moreov
mani
case
xmrv
critic
element
checklist
epidemiolog
agent
associ
diseas
might
known
guid
next
step
respons
xmrv
illustr
benefit
coordin
respons
formal
process
stakehold
includ
repres
blood
safeti
commun
conven
emerg
oper
center
determin
scientif
prioriti
would
ensur
blood
safeti
consid
optim
address
parallel
epidem
respons
prioriti
although
process
occur
tend
ad
hoc
made
systemat
infrastructur
enabl
effect
research
respons
exist
rare
tailor
agent
interest
may
known
respons
react
earli
stage
concern
blood
donor
issu
context
disast
plan
exist
within
american
red
cross
america
blood
center
welldevelop
network
contact
call
respons
threat
much
infrastructur
inform
remain
strong
long
expert
involv
prior
eid
respons
engag
activ
fund
program
nihfund
red
program
place
person
institut
memori
previou
experi
hiv
hcv
exist
formal
systemat
infrastructur
could
minim
consequ
transit
expertis
leadership
fade
collect
memori
infrastructur
must
flexibl
respond
variou
circumst
task
forc
suggest
follow
aid
develop
optim
risk
assess
manag
action
plan
creat
action
plan
clearli
defin
stakehold
decis
tree
threshold
action
trigger
caus
stakehold
conven
consid
propos
action
light
exist
evolv
evid
craft
coher
plan
action
includ
blood
safeti
priorit
issu
respons
emerg
epidem
pandem
develop
formal
process
identifi
exist
infrastructur
resourc
includ
network
contact
divers
expertis
need
access
engag
new
threat
emerg
basic
research
need
understand
whether
potenti
eid
infect
human
natur
immun
respons
human
agent
anim
reservoir
tissu
tropism
infect
transmiss
agent
found
whether
long
agent
surviv
blood
compon
storag
condit
whether
agent
transmit
transfus
transmit
diseas
penetr
shortand
longterm
clinic
consequ
infect
blood
recipi
research
inform
recognit
potenti
threat
trigger
threshold
action
decis
respons
action
viru
discoveri
research
program
also
benefici
establish
background
atla
virus
present
blood
suppli
illustr
xmrv
experi
corrobor
report
indic
eid
may
threat
separ
independ
laboratori
top
prioriti
larg
donor
donorrecipi
repositori
valuabl
resourc
evalu
transfus
transmiss
risk
optim
support
research
complex
exist
program
capabl
address
public
health
risk
extrem
valuabl
usual
fund
mechan
govern
agenc
nih
grant
slow
recognit
public
health
threat
trigger
activ
rapid
fund
mechan
andor
abil
redirect
exist
research
program
fund
toward
data
collect
specimen
bank
test
formal
risk
assess
mechan
need
support
research
redirect
laboratori
toward
address
potenti
threat
without
risk
neg
consequ
career
core
longterm
research
focu
laboratori
relev
dhh
agenciesnih
cdc
fdashould
work
togeth
creat
coher
approach
flexibl
fund
mechan
identif
exist
program
util
reprogram
need
aris
state
agenc
involv
need
process
newli
creat
rapid
respons
fund
mechan
would
allow
flexibl
involv
biotechnolog
diagnost
industri
fda
earli
possibl
enabl
rapid
develop
approv
test
address
proprietari
interest
nongovernment
nonprofit
privat
organ
move
quickli
often
best
establish
key
collabor
relev
industri
partner
develop
serolog
nat
screen
test
intramur
research
program
nih
cdc
instrument
respond
previou
threat
task
forc
suggest
facilit
eid
risk
assess
research
includ
establish
process
corrobor
initi
find
separ
independ
laboratori
simultan
mobil
respons
establish
mechan
rapidli
support
assess
agent
preval
infect
associ
diseas
surviv
blood
compon
transfus
transmiss
capabl
remov
pathogen
reduct
creat
strengthen
link
among
larg
recipi
databas
donorrecipi
repositori
bioinformat
track
transfus
exposur
associ
diseas
outcom
trigger
activ
altern
rapid
fund
mechan
andor
abil
redirect
exist
research
program
fund
toward
data
collect
specimen
bank
risk
assess
public
health
threat
recogn
foster
collabor
biotechnolog
diagnost
industri
tool
avail
largescal
research
studi
prospect
screen
blood
donor
warrant
one
highest
prioriti
item
identifi
train
futur
blood
safeti
expert
enter
field
live
hiv
hbv
hcv
epidem
formal
document
exist
inform
respons
infrastructur
accomplish
task
forc
report
provid
record
fade
collect
memori
blood
safeti
commun
must
engag
junior
investig
activ
particip
take
leadership
role
futur
respons
eid
task
forc
suggest
blood
safeti
commun
formal
document
exist
inform
respons
infrastructur
help
mitig
effect
fade
collect
memori
engag
junior
investig
activ
particip
respons
eid
includ
assum
leadership
role
formal
aspect
eid
respons
effort
govern
broader
scientif
blood
safeti
commun
month
workshop
aabb
eid
group
transfusiontransmit
diseas
committe
respons
eid
supplement
agre
lead
effort
formul
manag
risk
assess
critic
compon
outlin
articl
integr
exampl
horizon
scan
outlin
appropri
research
studi
eg
repositori
prospect
questionnair
recipi
trace
intervent
would
need
consid
pilot
studi
intern
particip
fund
need
integr
blood
center
oper
involv
individu
focu
plan
futur
necessari
meet
major
theme
recognit
risk
assess
develop
research
train
futur
expert
